Trial site
Pro Life Medica Sp. z o.o.
Lublin, 20-412, PolandEU-13 widening countryNot linked to an institution yet
- 7running trials
- 12closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 24 trials
- Phase 43 trials
- Status
- Completed12 trials
- Active, not recruiting5 trials
- Recruiting2 trials
- Lead sponsor
- Argenx2 trials
- Janssen Research & Development, LLC2 trials
- AstraZeneca1 trial
- Bristol-Myers Squibb1 trial
- Celldex Therapeutics1 trial
- and 12 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinical outcomes in patients with knee osteoarthritis – ZOOM-IN: A randomized, double-blind, placebo-controlled, parallel, multicentre clinical trial
2023-505875-56-00· Phase 4· KRKA tovarna zdravil d.d. Novo mesto· Source
Completed
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)
NCT06684847· Phase 3· Argenx· Source
Completed
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
2024-510826-16-00· Phase 3· Mabxience Research S.L.· Source
Completed
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· Phase 3· Dr Reddy's Laboratories Limited· Source
Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
NCT06920771· Phase 3· HAL Allergy· Source
Completed
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· Phase 3· Incyte Corporation· Source
Completed
Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS)
2023-503915-14-00· Phase 2· Argenx· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· Phase 3· Takeda· Source
Completed
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802· Phase 3· AstraZeneca· Source
Completed
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source
Completed
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
NCT04306315· Phase 4· LEO Pharma· Source
Completed
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
NCT04921384· Phase 3· H. Lundbeck A/S· Source
Report an error